Angiogenesis, the formation of new blood vessels, is a complex and dynamic process
regulated by various pro-and anti-angiogenic molecules, which plays a crucial role in tumor …

Abstract Introduction: The American Thyroid Association appointed a Task Force of experts
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …

Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor
(MET), vascular endothelial growth factor receptor 2, and rearranged during transfection …

Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Purpose: Medullary thyroid cancer (MTC) accounts for about 2% of all thyroid cancer, but
has a relatively poor prognosis compared with differentiated thyroid cancer. Anlotinib is a …

Purpose: Positive results of phase I studies evaluating lenvatinib in solid tumors, including
thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC) …

Medullary thyroid carcinoma (MTC) is a rare type of tumor that originates from thyroid C cells
and accounts for 2–4% of all malignant thyroid neoplasms. MTC may occur sporadically or …

Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Background: The prognosis of advanced or metastatic medullary thyroid carcinoma (MTC) is
poor, and there are few therapeutic options. Anlotinib has previously shown promising …

Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is
generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such …